{"name":"Geron Corporation","slug":"geron","ticker":"GERN","exchange":"NASDAQ","domain":"geron.com","description":"Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.","hq":"Foster City, CA","founded":0,"employees":"258","ceo":"John A. Scarlett","sector":"Hematology","stockPrice":1.75,"stockChange":0.01,"stockChangePercent":0.57,"marketCap":"$1.1B","metrics":{"revenue":1065000,"revenueGrowth":1,"grossMargin":97.4,"rdSpend":0,"netIncome":-83500000,"cash":357919008,"dividendYield":0,"peRatio":21.9,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Rytelo first approved","drug":"Rytelo","drugSlug":"imetelstat","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-13","label":"Rytelo PHASE2,PHASE3 readout","drug":"Rytelo","drugSlug":"imetelstat","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"Imetelstat patent cliff ($0.0B at risk)","drug":"Imetelstat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rytelo","genericName":"IMETELSTAT","slug":"imetelstat","indication":"Low- to Intermediate-1 Risk MDS with Transfusion-Dependent Anemia","status":"marketed"}]}],"pipeline":[{"name":"Rytelo","genericName":"IMETELSTAT","slug":"imetelstat","phase":"marketed","mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide.","indications":["Low- to Intermediate-1 Risk MDS with Transfusion-Dependent Anemia"],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Geron Announces FDA Acceptance of Imetelstat NDA for Myelofibrosis","summary":"The FDA has accepted Geron's New Drug Application (NDA) for imetelstat, a telomerase inhibitor, for the treatment of myelofibrosis.","drugName":"Imetelstat","sentiment":"positive"},{"date":"2022-05-10","type":"earnings","headline":"Geron Reports First Quarter 2022 Financial Results","summary":"Geron reported its first quarter 2022 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2021-12-13","type":"deal","headline":"Geron Announces Collaboration with Janssen to Develop Imetelstat for Myelodysplastic Syndromes","summary":"Geron has entered into a collaboration with Janssen to develop imetelstat for the treatment of myelodysplastic syndromes.","drugName":"Imetelstat","sentiment":"positive"}],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNVlRKeXNyT3hLRTBoeUZqdTExSmhoZlRhUDZyWURuY1hYT256elRIek5UOG5kUDI4R3p1dzkxWHB3ZE9DUWh6Yl9RTkl2aWJPV2FDd2x4MktST1NBZjY5SDlVYUR6REdJcFBCaFkyMjhqb0ZHZVBBSFdMZGRlZi1wVGpwOHBxUklROU1TRENhQ3lwTjdCMmVXS3kwek02d2tKZDh5LUtDVFRvdjNvN2pJdnNPeXV0T1A1?oc=5","date":"2025-12-11","type":"pipeline","source":"Seeking Alpha","summary":"Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On Sidelines (GERN) - Seeking Alpha","headline":"Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On Sidelines (GERN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOGJXbW9sX0Vhbm0xV1VKUjJsQnRrRlJMRnpTaEpKWnhFZzIzaHNPbmN0ckJHMF9wWktHT0d4NXFiWUE1RTZyS1JLcnVZd0xtUXpCRS1zdkNNaER2dXpqX0lrVXJMRnZWT29OOFdTQkVoOGkyUVVrYU4zbnRscU1BUzdSaTJqQkpOUVh6UmJpeDhxSC1WbzlyeFhUWC0yQmpUOWxZWGRGdkVsSGEyWFoyYmJpQlc5Nmkta0MwY3ZsOWs?oc=5","date":"2025-12-11","type":"pipeline","source":"Stock Titan","summary":"Geron (Nasdaq: GERN) plans one-third cut as 2026 operating expenses expected below 2025 - Stock Titan","headline":"Geron (Nasdaq: GERN) plans one-third cut as 2026 operating expenses expected below 2025","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-27","type":"pipeline","source":"simplywall.st","summary":"Great week for Geron Corporation (NASDAQ:GERN) institutional investors after losing 71% over the previous year - simplywall.st","headline":"Great week for Geron Corporation (NASDAQ:GERN) institutional investors after losing 71% over the previous year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQdzA5UHZkQnZ6ZXU4VWpKNjAtSUYyZTcwUE1pQjByQUFlUWZsNzJlWVZ1Skpxc0puVlE0cmpnbDRMWlJONVQ1VG5HdHdJd1pJb1d3Vm92TmxIQmFtaU5hbmlGN24zdjh1UDN4dTVqRHVGOXBrbEg0Y1M1dXBjN0hUWkxhMzR5T19lc043bC13UGVtZWJvQURlazdVejFxTUd4TkNKNGJacUJ4RWdxb3NMTHdETE1GdkNKMjJxTw?oc=5","date":"2025-11-07","type":"deal","source":"Seeking Alpha","summary":"Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN) - Seeking Alpha","headline":"Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-19","type":"pipeline","source":"Insider Monkey","summary":"Geron Corporation (GERN) Announces Grant of Stock Options; Scotiabank Reiterates ‘Hold’ Rating - Insider Monkey","headline":"Geron Corporation (GERN) Announces Grant of Stock Options; Scotiabank Reiterates ‘Hold’ Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOR0ZJY0dzQ3ItaGNyZEFRQ2g1b3ZhUkhpaERiQktuQ3FqX0YweUxIdVVZUVFNTnprN202YkFEYjh5RkZ3c180RWtVR1hMc0xnd01oOU1QeVBWQmxteFlWQmljWVFRMWt0UG53bGdzZUFVMFF6Z253TktucmtWX3lJVk43YUM2RTFOQTFNalFpamd3MWVoTVV2MHVlZE1hZkZZSGI1UGVvd2tWTkNrOEVoTENYU1g4MEtUS0IxZGxpZmJNMEtITU4xZlF0WUdzSjJEbkhNUHhkZkFnaXpUQW03RA?oc=5","date":"2025-08-13","type":"pipeline","source":"Investing.com","summary":"Geron Corporation’s SWOT analysis: biotech stock faces growth hurdles amid positive outlook - Investing.com","headline":"Geron Corporation’s SWOT analysis: biotech stock faces growth hurdles amid positive outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOVUFPRHdPcjFMVnVtaGpmMmMwN3l2d1QtZVlnajM0TXh5YlV5dUozNkJyU0pmcGRycjVKOG9jNUp0V1hkelFxQVZkVkNUVXZWaGpQWHhTNG5XNDdZWjQ3RWFaME0yaklKNFhjOTZGLVY0VjRPSGJpNnNPNUhVYlBzTWFwSGFBdG5OOUE?oc=5","date":"2025-08-08","type":"pipeline","source":"Seeking Alpha","summary":"Geron: I Think We've Seen This Movie Before (NASDAQ:GERN) - Seeking Alpha","headline":"Geron: I Think We've Seen This Movie Before (NASDAQ:GERN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-20","type":"pipeline","source":"simplywall.st","summary":"Market Sentiment Around Loss-Making Geron Corporation (NASDAQ:GERN) - simplywall.st","headline":"Market Sentiment Around Loss-Making Geron Corporation (NASDAQ:GERN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-10","type":"pipeline","source":"simplywall.st","summary":"Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results - simplywall.st","headline":"Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jUnhaU0lUZ1RRbVJTRk1kLTFoOWN5SHZuSnJJTHZfNVZaYVFWbnNqTDRFcFNEQVh4RElrbkZING5pS0dZSUVoemMtTFNjLXdDeE9j?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"GERN Stock Price, News & Analysis - Stock Titan","headline":"GERN Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Imetelstat","drugSlug":"telomerase-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celgene","Janssen","Novartis"],"therapeuticFocus":["Hematology","Oncology"],"financials":{"source":"sec_edgar","revenue":1065000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":1065000,"period":"2017-12-31"},{"value":191000,"period":"2017-12-31"},{"value":163000,"period":"2017-09-30"},{"value":174000,"period":"2017-06-30"},{"value":537000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-83500000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":570540000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.75,"previousClose":1.74,"fiftyTwoWeekHigh":2.01,"fiftyTwoWeekLow":1.04,"fiftyTwoWeekRange":"1.04 - 2.01","fiftyDayAverage":1.58,"twoHundredDayAverage":1.38,"beta":0.67,"enterpriseValue":878620736,"forwardPE":21.9,"priceToBook":4.96,"priceToSales":6.1,"enterpriseToRevenue":4.78,"enterpriseToEbitda":-17.2,"pegRatio":0,"ebitda":-51079000,"ebitdaMargin":-27.8,"freeCashflow":-78356248,"operatingCashflow":-111037000,"totalDebt":121992000,"debtToEquity":54,"currentRatio":4.66,"returnOnAssets":-5.5,"returnOnEquity":-33,"analystRating":"","recommendationKey":"none","numberOfAnalysts":5,"targetMeanPrice":3.4,"targetHighPrice":5,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":77.9,"sharesOutstanding":640544661,"floatShares":510712664,"sharesShort":63223778,"shortRatio":3.24,"shortPercentOfFloat":9.9,"epsTrailing":-0.13,"epsForward":0.08,"revenuePerShare":0.28,"bookValue":0.35,"officers":[{"age":57,"name":"Ms. Michelle J. Robertson","title":"Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer"},{"age":58,"name":"Dr. Joseph Emile Eid M.D.","title":"Executive VP of Research & Development and Chief Medical Officer"},{"age":55,"name":"Mr. Harout  Semerjian","title":"CEO, President & Director"},{"age":null,"name":"Mr. Shanthakumar  Tyavanagimatt","title":"Senior VP & Chief Technical Officer"},{"age":null,"name":"Ms. Dawn  Schottlandt CFA","title":"Senior Vice President of Investor Relations & Corporate Affairs"},{"age":null,"name":"Ms. Aron  Feingold","title":"Vice President of Investor Relations & Corporate Communications"},{"age":50,"name":"Ms. Shannon T. Odam","title":"Executive VP & Chief People Officer"},{"age":null,"name":"Mr. Bryan  Ridgell","title":"Senior VP of Portfolio & Project Management and Chief of Staff"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.geron.com","phone":"650 473 7700"}}